European Child & Adolescent Psychiatry

, Volume 9, Supplement 1, pp S9–S19

Atypical neuroleptics in child and adolescent psychiatry

  • Helmut Remschmidt
  • K. Hennighausen
  • P. Heiset
  • W. Clement
  • E. Schulz
Article

DOI: 10.1007/s007870070015

Cite this article as:
Remschmidt, H., Hennighausen, K., Heiset, P. et al. European Child & Adolescent Psychiatry (2000) 9(Suppl 1): S9. doi:10.1007/s007870070015

Abstract

Atypical neuroleptics have enriched our treatment programmes, especially in childhood and adolescent schizophrenia. This article reviews the use of atypical neuroleptics in children and adolescents with schizophrenic disorder. It considers the receptor binding profile and pharmacological properties, indications, side effects, clinical applications and trials of atypical neuroleptics in comparison to the classical neuroleptic haloperidol in adolescent schizophrenia. Special emphasis is placed on the most common atypical neuroleptics clozapine, olanzapine and risperidone since most studies are carried out with these compounds, especially with clozapine. More clinically controlled trials have to be conducted since only one was performed so far. The place of the atypical neuroleptics is discussed and further studies are necessary in order to differentiate the indications tested so far and to find out if the spectrum of indications can be broadened.

Key words

Atypical neuroleptics schizophrenia child adolescent psychiatry 

Copyright information

© Steinkopff-Verlag 2000

Authors and Affiliations

  • Helmut Remschmidt
    • 1
  • K. Hennighausen
    • 1
  • P. Heiset
    • 1
  • W. Clement
    • 2
  • E. Schulz
    • 2
  1. 1.Dept. of Child and Adolescent PsychiatryPhilipps-UniversityMarburgGermany
  2. 2.Dept. of Child and Adolescent PsychiatryAlbert-Ludwigs-UniversityFreiburgGermany

Personalised recommendations